Ah then I asked ChatGPT to give me the documents and it doesn't...

Ah then I asked ChatGPT to give me the documents and it doesn't have them, what a bs from Chat GPT.

Lantheus Holdings (NASDAQ: LNTH) has secured certain rights related to potential mergers and acquisitions (M&A) involving Radiopharm Theranostics (ASX: RAD) through strategic agreements executed in 2024 and 2025.

Relevant Agreements

1. Share Subscription Agreement (June 2024): Lantheus Omega, a wholly owned subsidiary of Lantheus Holdings, entered into a Share Subscription Agreement with Radiopharm Theranostics. Under this agreement, Lantheus Omega purchased 149,625,180 ordinary shares of Radiopharm for a total amount of US$4.99 million at A$0.05 per share.StreetInsider.com+2GlobeNewswire+2

2. Purchase and Development Agreement (May 2024): Lantheus Holdings entered into a Purchase and Development Agreement with Radiopharm Theranostics and its subsidiary, Radiopharm Theranostics (USA), Inc. This agreement involved the acquisition of certain preclinical assets and the assumption of related licenses and obligations.GlobeNewswire+1

M&A Rights

While the specific details of any rights of first offer or last look are not explicitly outlined in the available public documents, the substantial equity stake acquired by Lantheus and the strategic nature of the agreements suggest a strong alignment between the two companies.Such arrangements often include provisions that provide the investor with preferential rights in the event of a potential sale or merger.